Loading
Diabetes Management and Research / Pancreatic Function and Diabetes / Diabetes and Associated Disorders · Journal article
The Russian Archives of Internal Medicine · August 13, 2026
A consensus or society position rather than new primary data.
This narrative review proposes that classification of diabetes into five clusters—SAID, SIDD, SIRD, MOD, and MARD—based on six clinical variables (age, BMI, HbA1c, GAD antibodies, HOMA2-B, HOMA-IR) may enable personalized treatment and complication prediction. Evidence from 2010–2023 literature suggests cluster-specific disease trajectories and complications, with regional and ethnic variation in cluster prevalence, but the source does not quantify treatment efficacy differences or provide original comparative outcome data.
Narrative literature review. Literature on diabetes mellitus classification and personalized treatment; regional/ethnic cohorts (South Asian, African) noted for epidemiological variation.. Intervention: Five-cluster classification model based on age, BMI at diagnosis, HbA1c, GAD antibodies, HOMA2-B, and HOMA-IR.. Compared with: Traditional T1D/T2D/gestational classification (mentioned in background but not directly compared with outcome data)..
Five-cluster model identifies distinct phenotypes: SIRD associated with nephropathy; SAID and SIDD with more severe complications including neuropathy and ketoacidosis MARD and MOD clusters show less severe metabolic and organ dysfunction, more common in obesity Regional and ethnic disparities observed: South Asians have higher SIRD incidence than African cohorts, where MOD is more prevalent
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider the five-cluster classification as a framework to stratify diabetes patients by metabolic phenotype and complication risk, tailor therapeutic intensity accordingly, and account for regional and ethnic variation in cluster prevalence. However, the review does not provide direct evidence of improved clinical outcomes with cluster-guided treatment.
A narrative review synthesizing evidence on a proposed reclassification framework for diabetes; provides conceptual guidance on personalized treatment approaches but does not present original efficacy data or comparative clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider the five-cluster classification as a framework to stratify diabetes patients by metabolic phenotype and complication risk, tailor therapeutic intensity accordingly, and account for regional and ethnic variation in cluster prevalence. However, the review does not provide direct evidence of improved clinical outcomes with cluster-guided treatment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Diabetes mellitus traditionally classified into type 1 (T1D), type 2 (T2D), gestational, and other specific types. A novel five-cluster model severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD). This new classification was based on six clinical variants: age, body-mass index at diagnosis, glycosylated hemoglobin, glutamic acid decarboxylase antibodies, homeostasis model assessment 2 beta and insulin resistance. This model enhances personalized treatment and complication prediction. Objective: This review evaluates the clinical and therapeutic implications of the five-cluster classification, synthesizing evidence from 2010–2023 to assess its impact on treatment efficacy and personalized care. Methods: This review was limited to the last 15-years and was done using PubMed, Web of Science and Google Scholar. Terms used included “precision therapy,” “diabetes sub-categories,” “SAID,” “SIDD,” “SIRD,” “MOD” and “MIRD.” Only preclinical and clinical data in English were used. Results: The five-cluster model highlights specific clinical trajectories: SIRD is associated with nephropathy, while SAID and SIDD clusters have more complications (e.g., neuropathy, ketoacidosis) severity. The metabolic and organ dysfunction (MARD and MOD) that is more common in obesity, is less severe. Validation studies have brought attention to regional and ethnic disparities in the distribution of SIRD and MOD; specifically, it seems that South Asians have a higher incidence of SIRD than African cohorts, where MOD is more prevalent. In conclusion, by customizing therapeutic applications to metabolic profiles, the five-cluster method promotes precision medicine; therapy ought to be in line with biology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.